An insight into the pathophysiology of thrombosis in antiphospholipid syndrome
Por:
Palomo I.G., Segovia F.M., Alarcon M.L., Fuentes B.Y., Pereira J.G., Rojas A., Forastiero R.
Publicada:
1 ene 2007
Resumen:
The antiphospholipid syndrome (APS) is a disorder which is characterized by the presence of autoimmune antiphospholipid antibodies (APL) and increased risk of thrombosis and fetal loss. APL are associated with recurrent abortions in APS patients and participate in the pathogenesis of venous or arterial thrombosis, although the underlying mechanisms are poorly understood. Antigens that are targeted by APL include beta 2 glycoprotein I and prothrombin. Pathological mechanisms of APL encompass inhibition of natural anticoagulants (protein C system, tissue factor pathway inhibitor, and annexin A5), inhibition of the fibrinolytic system, activation of endothelial cells, monocytes and platelets, and complement activation. In this review, we discuss the main targets of APL and prothrombogenic mechanisms of APL.
Filiaciones:
Palomo I.G.:
Department of Clinical Biochemistry and Immunohematology, Faculty of Health Science, Universidad de Talca, Talca, Chile, P.O. box: 747, Talca, Chile
Segovia F.M.:
Department of Clinical Biochemistry and Immunohematology, Faculty of Health Science, Universidad de Talca, Talca, Chile, P.O. box: 747, Talca, Chile
Alarcon M.L.:
Department of Clinical Biochemistry and Immunohematology, Faculty of Health Science, Universidad de Talca, Talca, Chile, P.O. box: 747, Talca, Chile
Fuentes B.Y.:
Department of Clinical Biochemistry and Immunohematology, Faculty of Health Science, Universidad de Talca, Talca, Chile, P.O. box: 747, Talca, Chile
Pereira J.G.:
Department of Hematology-Oncology, School of Medicine, Pontificia Universidad Catolica de Chile, Santiago, Chile
Rojas A.:
School of Medicine, Faculty of Health Sciences, Universidad Catolica del Maule, Talca, Chile
Forastiero R.:
Department of Hematology, Universidad Favaloro, Buenos Aires, Argentina
|